Swiss National Bank Sells 28,500 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Swiss National Bank trimmed its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,098,700 shares of the medical equipment provider’s stock after selling 28,500 shares during the quarter. Swiss National Bank owned 0.31% of Intuitive Surgical worth $370,657,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ISRG. Baystate Wealth Management LLC increased its stake in Intuitive Surgical by 150.0% in the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC increased its stake in shares of Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the last quarter. Atticus Wealth Management LLC increased its stake in shares of Intuitive Surgical by 85.4% during the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 41 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Intuitive Surgical during the 3rd quarter worth about $25,000. Finally, Headinvest LLC acquired a new position in shares of Intuitive Surgical during the 3rd quarter worth about $28,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Up 0.9 %

Shares of ISRG stock traded up $3.20 on Thursday, reaching $374.90. The company’s stock had a trading volume of 350,774 shares, compared to its average volume of 1,621,316. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The company has a market capitalization of $132.98 billion, a P/E ratio of 67.09, a PEG ratio of 4.79 and a beta of 1.39. The stock’s 50 day simple moving average is $385.79 and its 200-day simple moving average is $348.35.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 earnings per share. Research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Activity

In other news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 20,296 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,168,656.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 226,928 shares of company stock valued at $87,833,828. 0.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wells Fargo & Company lifted their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. BTIG Research increased their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Robert W. Baird lowered their price objective on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday, April 19th. Finally, Jefferies Financial Group raised their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.